Àâòîðèçàöèÿ
Ïîèñê ïî óêàçàòåëÿì
Shepherd Ph.S. (ed.), Dean Ch. (ed.) — Monoclonal Antibodies: A Practical Approach
Îáñóäèòå êíèãó íà íàó÷íîì ôîðóìå Íàøëè îïå÷àòêó?
Íàçâàíèå: Monoclonal Antibodies: A Practical ApproachÀâòîðû: Shepherd Ph.S. (ed.), Dean Ch. (ed.) Àííîòàöèÿ: Monoclonal Antibodies: A Practical Approach covers the preparation, testing, derivation, and applications of monoclonal antibodies. New immunological techniques incorporating tried and tested methodologies are described, making the book of interest to established and inexperienced immunologists. Both the standard somatic hybridization technique and recombinant techniques, including the use of phage libraries, for the preparation of rodent and human monoclonal antibodies are described. Protocols for both the small and large scale production are detailed, as well as purification and labelling (with both radioisotopes and non-radioisotopes) methods. The applications of monoclonal antibodies in immunoblotting, enzyme linked immunoassays, immunofluorescence, and FACS analysis are all covered in detail. Finally protocols are given for the use of monoclonal antibodies in rheumatoid arthritis, tissue typing, detecting DNA modified during chemotherapy, and in the clinical analysis of transplantation samples for malignancy. This book will therefore be an invaluable laboratory companion to anyone using monoclonal antibodies in their research.
ßçûê: Ðóáðèêà: Ìåäèöèíà è çäðàâîîõðàíåíèå /Ñòàòóñ ïðåäìåòíîãî óêàçàòåëÿ: Ãîòîâ óêàçàòåëü ñ íîìåðàìè ñòðàíèö ed2k: ed2k stats Ãîä èçäàíèÿ: 2000Êîëè÷åñòâî ñòðàíèö: 479Äîáàâëåíà â êàòàëîã: 16.02.2007Îïåðàöèè: Ïîëîæèòü íà ïîëêó |
Ñêîïèðîâàòü ññûëêó äëÿ ôîðóìà | Ñêîïèðîâàòü ID
Ïðåäìåòíûé óêàçàòåëü
Endotoxins, contamination of mAbs 177—179 Enhanced chemifluorescence (ECF) 279 Enhanced chemiluminescence (ECL) 278 Enhanced chemiluminescence (ECL), re-probing blots 281—282 Enhanced chemiluminescence (ECL), secondary mAbs, horseradish peroxidase-conjugated 277—278 Enzyme labelling 240—241 303—305 Enzyme linked assays see “ELISA” Epidermal growth factor receptor (EFGR), as immunogen 4 Epitopes, mapping 295 Epitopes, non-recognition 277 Epitopes, reactivity 20—21 Epstein-Barr virus, cloning 121—122 Epstein-Barr virus, microtitre assay 121 Epstein-Barr virus, preparation of lymphocytes 113—114 Epstein-Barr virus, screening techniques 120—121 Epstein-Barr virus, selection of donor 113 Epstein-Barr virus, transformation mAbs to blood group antigens 114—117 Equines, myeloma cell lines 3 Escherichia coli TG1 strain, filamentous phage titration 69—70 Escherichia coli TG1 strain, preparation for electroporation 52—54 Ethanolamine, serum supplement 128 Ethidium bromide, caesium chloride isopycnic centrifugation 46—49 Ethylene-bis-succinimidyl-succinate (EGS) 362 F conjugative plasmids 69—70 FACS (fluorescence activated cell sorter) analysis 371—389 Fast Red TR salt chromogen, alkaline phosphatase 404—405 FASTA database search program 63 Feeder cells, preparation 118—119 Fermenters, airlift 136 Fermenters, stirred bioreactors 134—135 Fetal calf serum see “Serum” Ficoll-Hypaque gradient centrifugation 385 Filamentous phage, antibody display and titration 69—70 Fixation procedures, BrdUrd flow cytometry technique 345—346 Fixation procedures, immunofluorescence 358 Fixation procedures, paraffin wax embedded tissues 392—393 Fixatives 392 Fixatives, glutaraldehyde 361 Fixatives, methanol/acetone 361 Fixatives, paraformaldehyde 359 Fluidized bed bioreactors 142—143 Fluorescein labelling 242 Fluorescence activated cell analysis (FACS) 371—389 Fluorescence activated cell analysis (FACS), clinical samples 376 Fluorescence activated cell analysis (FACS), dual fluorescence 374—376 Fluorescence activated cell analysis (FACS), fluorochromes 371—389 Fluorescence activated cell analysis (FACS), quality control 376—377 Fluorescence activated cell analysis (FACS), ready-conjugated mAbs 373—374 Fluorescence microscopy, equipment 363—365 Fluorescent staining 356—361 Fluorescent staining, amine group-specific dye derivatives 356 Freeze storage 395 Freeze-substitution, resin embedding 256—258 Freund’s adjuvant 4 Fv (heavy and light chain variables) see “Single chain Fv (ScFv) antibodies” Fv regions modelling 62 Gel filtration (size exclusion chromatography) 168—169 Glutaraldehyde, fixation 361 Glycosylation sites, N-, O- 60 Glycosylation sites, removal 64 Glycosylation, plant recombinant proteins 185—186 Gold reagents, immunogold probes 247—263 Gold reagents, multiple labelling 261—262 Gold reagents, pre-embedding labelling 249—250 GRP94 183 Guy’s-13 IgGl 183—186 Haematological samples, FACS analysis 371—389 Haematological values 377 Haematopoietic transplantation, Campath-1M, paediatric 383—384 Halogenated pyrimidines, BrdUrd flow cytometry 341—353 Harms buffer 269 Harvesting and concentration of mAbs 143—145 HAT selection medium 11 Helper phage M13K07 72—73 84 Heterohybridomas, Epstein-Barr virus transformation 111—123 HGPRT, loss in myelomas 3 High cell density culture systems 137—143 High temperature antigen retrieval (HTAR) 397—398 High temperature antigen retrieval (HTAR), section adhesion 394 Hoffmeister series 156 170 Hollow fibre (Acusyst) culture 138—139 Hollow fibre dialyser assembly 151—153 Horseradish peroxidase in proximity selection 80—83 Horseradish peroxidase, 3,3’-diaminobenzidine (DAB) chromogen 402—403 Horseradish peroxidase, 3-amino-9-etnylcarbazole chromogen 403 Horseradish peroxidase, catalyzed enzyme reporter deposition (CARD) 79 Horseradish peroxidase, HRP-conjugated secondary Abs 280 Horseradish peroxidase, HRP-labelling 303—304 Horseradish peroxidase, secondary mAbs 277—278 Horseradish peroxidase, secondary mAbs, ECL detection 281 Horseradish peroxidase, streptavidin-HRP 82 Host for immunization, choice 3—4 Human B-cells, EBV virus transformation 116 Humanized antibody design 58—65 Humanized antibody design, choice of human acceptor frameworks 62—63 Humanized antibody design, cycle 59 Humanized antibody design, downstream primers for DNA recovery by RT-PCR 100—101 Humanized antibody design, identification of putative backmutations 63—64 Humanized antibody design, mAb therapies for rheumatoid arthritis 449—461 Humanized antibody design, mAbs to blood group antigens 111—123 Humanized antibody design, modelling Fv reions 62 Humanized antibody design, source donor amino acid sequences 59—61 Hybridomas, cloning 18 Hybridomas, comparison of culture systems 145 Hybridomas, culture supernatants; screening for specific Abs 12—19 Hybridomas, generation (cell fusion) 11 Hybridomas, production levels of Ab 151 Hybridomas, screening for anti-DNA Abs 415 Hybridomas, small-scale production of mAbs 125—147 Hybridomas, small-scale production of mAbs, kinetics 126 Hybridomas, vH/K construction, ARM display 93—96 Hydrophilic interaction, chromatography 173 Hydrophobic interaction, chromatography 169—172 Hydroxyapatite 172 Hypoxanthine, aminopterin, thymine (HAT) selection medium 11 Hypoxanthine-guanine, phosphoribosyl transferase (HGPRT) 3 I-125 radiolabelling, Chloramine-T method 209—210 307—308 ICAMs: mAbs in RA 454 IgG, alkaline phosphatase labelling 304—305 IgG, ammonium sulfate precipitation 144 157—158 IgG, anti-CD4 mAb with human IgG1 (cM-T412) 456 IgG, biotin labelling 243 305—306 IgG, bovine, potential contamination of media 152—153 IgG, ELISA, generic method 175—177 IgG, genes, phage libraries 67—89 IgG, human IgG1 Fc see “Campath-1H” IgG, hydrophobic interaction, chromatography 169—172 IgG, immunoaffinity purification 162 IgG, labelling sites 238—239 IgG, labelling with alkaline phosphatase 304—305 IgG, plants, transgenic 181—206 (see also “Immunoglobulins; single chain Fv (ScFv) antibodies”) Imaging detectors for CCD cameras 365—367 Imaging detectors for colour cameras 367 Imaging detectors for sectioning microscopy 365—367 Immobilized antigen, immunotubes 71—74 Immobilized metal affinity, chromatography 166—168 Immunization route 8 Immunoaffinity purification 162 Immunoaffinity, analysis of purified antigen 336—337 Immunoaffinity, antigen binding 331—333 Immunoaffinity, antigen reconstitution 335—336 Immunoaffinity, chromatography 319—339 Immunoaffinity, coupling carbodiimide 324—325 Immunoaffinity, coupling chemistry 321—322 Immunoaffinity, coupling cyanogen bromide 322 Immunoaffinity, coupling indirect via protein A/G 327—329 Immunoaffinity, coupling monitoring 329—330 Immunoaffinity, coupling N-hydroxysuccinimide ester 324 Immunoaffinity, coupling orientational direct 325—327 Immunoaffinity, crosslink stability 329—330 Immunoaffinity, elution 334—335 Immunoaffinity, matrix 320—330 Immunoaffinity, sample preparation 330—331 Immunoassays 297—318 Immunoassays, Ab selection 297—298 Immunoassays, assay standards, selection 298—299 Immunoassays, assay turnaround time 300—301 Immunoassays, buffers 315—316 Immunoassays, labelling and detection of Ab/Ag 303—309 Immunoassays, sample matrix 299 Immunoassays, sample preparation and dilution 299—300 Immunoassays, solid support and separation options, double Ab precipitation 302 Immunoassays, solid support and separation options, magnetic particles 302 Immunoassays, solid support and separation options, microtitre plates 301 Immunoassays, solid support and separation options, PEG 302 Immunoassays, solid support and separation options, scintillation proximity 303 Immunoassays, types 309—317 Immunoassays, types, competitive binding 309—311 Immunoassays, types, sandwich 311—315 (see also “ELISA”) Immunoblotting, cellular antigens 270—283 Immunoblotting, membrane matrices 275 Immunoblotting, procedure 278—279 Immunoblotting, troubleshooting 282—283 Immunocytochemistry, detection methods, alkaline phosphatase anti-ALP (APAAP) method 400—401 Immunocytochemistry, detection methods, avidin-biotin complex 398—400 Immunocytochemistry, detection methods, enhanced polymer (dextran) 400 Immunocytochemistry, progressive lowering of temperature (PLT) 248—249 255—256 Immunocytochemistry, quality control 407 Immunocytochemistry, reporter molecules 402—405 Immunocytochemistry, resin sections 258—261 Immunocytochemistry, staining 391—409 Immunofluorescence microscopy 355—370 Immunofluorescence microscopy, data analysis and presentation 367—368 Immunofluorescence microscopy, imaging detectors for sectioning microscopy 365—367 Immunofluorescence microscopy, immunolabelling of living cells 368—369 Immunofluorescence microscopy, microscopes 363—365 (see also “Fluorescence”) Immunofluorescence, cell fixation 358 Immunofluorescence, direct/indirect staining 355—356 Immunofluorescence, subcellular localization of proteins 287 Immunogens in vitro somatic hybridization 4 Immunoglobulins genes, phage libraries 67—89 (see also “IgG; single chain Fv (ScFv) antibodies”) Immunogold probes light and electron microscopy 247—263 Immunolabelling living cells 368—369 Immunoprecipitation, cellular antigens 289—295 Immunoprecipitation, equipment and methods 293—295 Immunoprecipitation, specific antigen 22 Immunoprecipitation, troubleshooting 292 Immunoprecipitation, under disruptive conditions 292 Immunosuppression vs immunological tolerance 432—433 In vitro display technologies see “ARM display” In vitro somatic hybridization, antigen preparation 5—7 In vitro somatic hybridization, cell fusion 11 In vitro somatic hybridization, cloning hybridomas 18 In vitro somatic hybridization, epitope reactivity 20—21 In vitro somatic hybridization, growth of myeloma cell lines 9 In vitro somatic hybridization, immunization route 7—9 In vitro somatic hybridization, immunogen choice 4 In vitro somatic hybridization, isotyping 20 In vitro somatic hybridization, preparation of cells for fusion 10 In vitro somatic hybridization, screening hybridoma culture supernatants for Ab 12—19 In vitro somatic hybridization, use and characterization of Ab obtained 19—22 Indium-111, in vivo applications 219—223 Insulin, serum supplement 128 Interleukins, anti-IL6 and -IL6R mAbs 453—454 Iodine-123, in vivo applications 218 Iodine-125, characteristics and techniques 14 208—217 Iodine-125, Chloramine-T method 209—210 307—308 Iodine-125, tyrosine incorporation 307 Iodine-131, radioimmunotherapy applications 230 231 Iodogen, labelling with I-125 209—211 307 Ion exchange chromatography 162—166 Iso-electric focusing, 2D PAGE 283 285 Isotyping, monoclonal antibodies 20 Jumping-PCR, Fv assembly method 32 39—41 Kabat scheme, CDR loops 61 Lactoferrin, serum supplement 128 Lactoperoxidase system 215 LacZ promoter 46 68 LAL test, endotoxin contamination of mAbs 177—179 Lanthanide fluorophores, labelling 306—307 Leucocyte function-associated antigen-1 (LFA-1) 454 Leukaemias, chronic lymphocytic leukaemia 382 Library construction see “Phage libraries” Ligand binding assays, anti-receptor Abs 17 Light microscopy, 3D sectioning microscope 364 Light microscopy, confocal laser scanning 364—365 Light microscopy, immunofluorescence 355—370 Light microscopy, immunogold probes 247—263 Light microscopy, immunolabelling 253 Linker DNA preparation assembly 39—41 Linker DNA preparation single chain Fv (ScFv) antibodies 37—39 List of suppliers 463—468 Lowicryl resin embedding, freeze-substitution 256—258 Lysis buffers 266—268 Macrophage inflammatory, protein (MIP-1-alpha) 82 83 Magnetic particles, antigen or streptavidin coupled 98—99 Magnetic particles, immunoassays 302 Mannopine synthase 187 Mass spectrometry 308—309 Membrane culture systems, miniPerm bioreactor 139—140 Methanol/acetone fixation 361 Methionine-S-35, radiolabelling 292—293 Microtitre plates 301 Microtubules, multiple labelling 261—262 Microwave oven high temperature antigen retrieval (HTAR) 398 Mini gel systems, SDS-PAGE 270—273 Minimal medium bacteria 70 MiniPerm bioreactor systems 139—140 Mixed micelle detergent (RIPA) buffer 266—268 292 Monoclonal antibodies yields, comparison of culture systems 145 (see also “Human monoclonal antibodies; protein purification technology”) Monoclonal antibodies, analysis of purity and activity 174—179 Monoclonal antibodies, applications in protein characterization 296 Monoclonal antibodies, characterization of cellular antigens 265—296 Monoclonal antibodies, comparison of culture systems 145 Monoclonal antibodies, direct/indirect labelling 237—246 Monoclonal antibodies, direct/indirect labelling with biotin 243 Monoclonal antibodies, direct/indirect labelling with choice 238 Monoclonal antibodies, direct/indirect labelling with digoxigenin 244 Monoclonal antibodies, direct/indirect labelling with enzyme 240—241 Monoclonal antibodies, direct/indirect labelling with evaluation 244—246 Monoclonal antibodies, direct/indirect labelling with fluorescein 242 Monoclonal antibodies, direct/indirect labelling with general aspects 238—240 Monoclonal antibodies, direct/indirect labelling with purification and storage 239—240 Monoclonal antibodies, direct/indirect labelling with scale and ratios 239 Monoclonal antibodies, EM immunolabelling 247—263 Monoclonal antibodies, fluorescent staining 356—361 Monoclonal antibodies, full-length and multimeric 183—185 Monoclonal antibodies, harvesting and concentration 143—145 Monoclonal antibodies, historical note 1 Monoclonal antibodies, humanized antibody design 58—65 Monoclonal antibodies, isolation from tissue culture supernatant 149—180 Monoclonal antibodies, isotyping 20 Monoclonal antibodies, non-radioactive antibody probes 237—246 Monoclonal antibodies, plants 181—206 Monoclonal antibodies, radiolabelling 207—236 307—308 Monoclonal antibodies, small-scale production 125—147 Monoclonal antibodies, storage 173—174 Monoclonal antibodies, use and characterization 19—22 Mononuclear cell fraction (MNC), bone marrow 381—382 Mononuclear cell fraction (MNC), bone marrow, cytokines 384—389 Mononuclear cell fraction (MNC), bone marrow, T cell depletion 383 Mononuclear cell fraction (MNC), Ficoll — Hypaque gradient centrifugation 385 Mouse antibodies, downstream primers for DNA recovery by RT-PCR 100—101 Mowiol mounting medium 359 mRNA, cDNA: mRNA hybrid 31—32 mRNA, isolation of total mRNA from spleen 27—29 mRNA, poly(A+), isolation 30—31 Multiple cloning site (MCS) 190 Multiwell plates, antigen coating 12—13 16 Multiwell plates, live cells 16
Ðåêëàìà
|
|
Î ïðîåêòå